Hosted on MSN12d
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
AstraZeneca AZN stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations ...
BioSpace1d
AstraZeneca Gets Full FDA Approval for CMS-Selected Lymphoma Treatment
The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...
The Pharma Letter1d
AstraZeneca's Fasenra set to revolutionize COPD treatment
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
J&J's combo extends patients' lives in head-to-head study with AstraZeneca's drug
Johnson & Johnson said on Tuesday its chemotherapy-free combination treatment showed a meaningful improvement in extending ...
AstraZeneca gains on getting nod from CDSCO to import new drug Eculizumab
AstraZeneca Pharma India rose 1.10% to Rs 10,754 after the firm received approval from the Central Drugs Standard Control Organisation (CDSCO) to import pharmaceutical formulations of eculizumab ...
Reuters26d
AstraZeneca withdraws application for lung cancer drug in EU
LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L), opens new tab has ... came following feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency.